Replies to post #100289 on Biotech Values

[iwfal]

HCV relapse times

But my specific point was that the relapse time constant was shorter under ifn monotherapy

After thinking about it it occurred to me that although I had seen multiple papers indicating SVR12 or less was good enough to claim successful treatment of HCV on ifn monotherapy (see first link below for example) I hadn't really confirmed that it WASN'T good enough as a metric for ifn+rib. And in fact I found at least one paper indicating SVR12 is good enough for ifn+rib. See second link below:

http://journals.lww.com/jcge/Abstract/1998/04000/Hepatitis_C_Viral_RNA_Status__at_Two_Weeks_of.9.aspx

http://www.ihlpress.com/pdf%20files/hepdart09_presentations/oral_ii/12_martinotHEPDART%20PC.pdf

Sooo, the relapse kinetics of ifn monotherapy and ifn+rib may not be that different. But/thus SVR12 might actually be a very good proxy for SVR24.